Growth Response in Girls With Turner Syndrome

PHASE4CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

September 23, 1996

Primary Completion Date

May 21, 2003

Study Completion Date

May 21, 2003

Conditions
Genetic DisorderTurner Syndrome
Interventions
DRUG

somatropin

0.9 UI/kg/week. Subcutaneous injection for 3 years

DRUG

somatropin

1.8 UI/kg/week. Subcutaneous injection for 3 years

Trial Locations (15)

25030

Novo Nordisk Investigational Site, Besançon

31059

Novo Nordisk Investigational Site, Toulouse

33000

Novo Nordisk Investigational Site, Bordeaux

35056

Novo Nordisk Investigational Site, Rennes

37044

Novo Nordisk Investigational Site, Tours

38043

Novo Nordisk Investigational Site, Grenoble

54511

Novo Nordisk Investigational Site, Vandœuvre-lès-Nancy

59037

Novo Nordisk Investigational Site, Lille

59385

Novo Nordisk Investigational Site, Dunkirk

76031

Novo Nordisk Investigational Site, Rouen

Unknown

Novo Nordisk Investigational Site, Lorient

Novo Nordisk Investigational Site, Paris

Novo Nordisk Investigational Site, Reims

Novo Nordisk Investigational Site, Tarbes

06202

Novo Nordisk Investigational Site, Nice

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01734486 - Growth Response in Girls With Turner Syndrome | Biotech Hunter | Biotech Hunter